ERBB2 and breast carcinoma: The DS8201‐A‐J101 (NCT02564900) trial was conducted to evaluate the safety, efficacy, and pharmacokinetics of T‐DXd in patients with advanced HER2‐positive gastric or gastroesophageal and breast cancer that had not responded to standard treatments.121